Nanobiotix

Update in progress

NBTX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Nanobiotix S.A. is a clinical-stage biotechnology company developing cancer therapies and other unmet medical needs. Its lead candidate, NBTXR3, is a sterile suspension of crystalline hafnium oxide nanoparticles designed to treat multiple cancers, including soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. It partners with Lian Oncology to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the Paris-based company.

Company score

Sentiment: 0.27; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationFrance
CEODr. Laurent Levy Ph.D.
Founded2003
Employees100
Websitewww.nanobiotix.com

Identifiers

ISINUS63009J1079
FIGIBBG00Y9D2SW8
CIK0001760854